B lymphocyte-induced maturation protein 1 (BLIMP-1)

B lymphocyte-induced maturation protein 1 (BLIMP-1), encoded by the PRDM1 gene, is a master regulator transcription factor essential for the terminal differentiation of B cells into antibody-secreting plasma cells (UniProt O75626). It functions primarily as a transcriptional repressor, silencing genes required for B-cell proliferation and identity, such as c-Myc and PAX5, thereby facilitating the transition to a secretory state (PubMed: 12796776). Beyond B cells, BLIMP-1 plays critical roles in T-cell homeostasis, germ cell specification, and the development of various tissues (PubMed: 21664243). Dysregulation of BLIMP-1 is strongly linked to hematopoietic malignancies, particularly diffuse large B-cell lymphoma (DLBCL) where it often acts as a tumor suppressor, and autoimmune diseases like systemic lupus erythematosus (SLE) where its overactivity or deficiency can disrupt immune tolerance (PubMed: 16415865, PubMed: 24610275). While direct pharmacological targeting of BLIMP-1 remains challenging due to its nature as a transcription factor, it is a focal point for therapeutic strategies aimed at modulating plasma cell-mediated diseases and enhancing anti-tumor immunity. Current clinical approaches often involve drugs like Bortezomib that target the plasma cell population regulated by BLIMP-1 (PubMed: 19106067). Additionally, research into small molecule inhibitors and antisense oligonucleotides is ongoing to directly modulate its activity in cancer and autoimmunity (PubMed: 30249034).

Other names

PRDM1PR domain zinc finger protein 1BLIMP1

Transcriptional repression of genes such as PAX5 and MYC to promote terminal differentiation of B cells into plasma cells (PubMed: 12796776).